Research Spotlight: Factors Contributing to Treatment Resistance in CAR T Therapies for Solid Tumors
Researchers used a unique 3D microfluidic model of tumors to investigate the mechanisms of treatment resistance to CAR-T cells.
Research at Massachusetts General Hospital includes multitude of hospital-wide centers, institutes and programs as well as collaborations with other institutions.
Researchers used a unique 3D microfluidic model of tumors to investigate the mechanisms of treatment resistance to CAR-T cells.
Researchers found that injectable naltrexone had the fewest reported GI and liver-related side effects compared to the other drugs.
Researchers found that genetic swaps in the gut microbiome are occurring much more frequently than previously thought and detected more than 100,000 swaps that hadn’t been seen before.
Dan G. Duda, DMD, PhD, is the corresponding author of a paper published in Cancer Immunology Research, “Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma.”
Shadmehr (Shawn) Demehri, MD, PhD, is the corresponding author of a paper published in Cancer Cell, “Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin.”
A deeper understanding of astrocytes’ roles is essential for developing targeted therapies to manage or prevent Alzheimer's disease.